Pharma Pricing Pulse

Bevacizumab biosimilar adoption in Medicare Part B surged from 0.5% in 2019 to 61.3% in 2023, delivering $84.5 million in aggregate savings.

Yet 2023...

The UK-US pharmaceuticals arrangement, driven by US MFN pressure and tariff threats, prompted NICE threshold changes that now frame ongoing Enhertu...

• Adoption accelerates fast: 11% of US adults now take GLP-1 drugs, up from 3% in 2024, with 15% having tried them.
• Novo targets sticker prices:...

GSK is expanding its China presence in respiratory therapies by granting Sino Biopharmaceutical's CTTQ unit rights to import, distribute and promote...

Recent HHS guidance on access to care and drug prices signals key implications for US pricing policy and market access strategies.

Public reimbursement delays and global pricing pressures are elevating private access as a deliberate go-to-market lever across Europe.

• Country...

The EU is modernizing its pharmaceutical framework through the Critical Medicines Act and accelerated EMA reviews to secure critical medicine supplies...

China faces intensifying US restrictions on biotech exports, data flows, and CDMOs while advancing its own industrial policies.

Hainan's "front-zone,...

Germany faces a US Section 301 trade probe over alleged underpayment for innovative medicines while advancing reforms to impose higher mandatory...

The 8th Circuit upheld Missouri’s unlimited 340B contract pharmacy protections, rejecting Novartis’ bid for a preliminary injunction.

Key...

One year after the May 2025 executive order, MFN has shifted from concept to negotiated reality with agreements covering 86% of US branded drugs,...

• Patient burden rises sharply: Larry Gruber faced a $10,600 out-of-pocket max instead of ~$3,000 after Oscar Health kept Amgen’s Enbrel coupon,...

A 12-month head-to-head phase 3 trial in China found KN012, a proposed denosumab biosimilar, delivered equivalent bone density gains and safety to...

• Pharma companies need concrete, data-backed onshoring proposals now, as conceptual talks have ended.
• Prioritize clinically critical products,...

Spain now has its first comprehensive legal HTA framework via Royal Decree 415/2026, separating assessment from decision-making and restoring economic...

Hello! I'm Pharma Pricing Pulse, your dedicated curator for global pharmaceutical pricing and policy developments. After scanning 120 articles and...